期刊
AMERICAN JOURNAL OF CARDIOLOGY
卷 108, 期 3, 页码 52B-58B出版社
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjcard.2011.03.016
关键词
-
资金
- Novo Nordisk
- National Institutes of Health [TINSAL-2D]
- Tullis-Tulane Chair of Diabetes
- Susan Harling Robinson Fellowship in Diabetes Research
- Tullis-Tulane Alumni Chair in Diabetes
- Daiichi-Sankyo Co. Ltd.
- Eli Lilly and Company
- Halozyme Therapeutics
- Novo Nordisk A/S
- Pamlab
- Reata Pharmaceuticals, Inc.
- sanofi-aventis
- Biodel Inc.
Research has substantiated that patients with type 2 diabetes mellitus are at increased risk for cardiovascular (CV) disease. It is well established that aggressive management of metabolic risk factors is critical to reducing morbidity and mortality in patients with diabetes. A number of clinical trials are currently focusing on evaluating the safety and efficacy of therapeutic approaches to diabetes. These trials will provide additional information on the role of aggressive management of glucose in patients with diabetes and CV risk. This article provides a summary of these ongoing trials, and discusses the impact of glycemic control and strategies to promote CV risk reduction in patients with diabetes. (C) 2011 Published by Elsevier Inc. (Am J Cardiol 2011;108[suppl]:52B-58B)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据